EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Production and Immunogenicity of FeLV Gag-Based VLPs Exposing a Stabilized FeLV Envelope Glycoprotein

Raquel Ortiz iD, Ana Barajas, Anna Pons-Grífols iD, Benjamin Trinité iD, Ferran Tarrés-Freixas iD, Carla Rovirosa iD, Víctor Urrea iD, Antonio Barreiro iD, Anna Gonzalez-Tendero, Maria Rovira-Rigau, Maria Cardona, Laura Ferrer und 4 weitere

Viruses · 2024

DOI: 10.3390/v16060987 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Raquel Ortiz und 15 weiteren Autor:innen. Beteiligte Einrichtung: IrsiCaixa, 08916 Badalona, Spain. Hauptthemen laut MEDLINE: Antibodies, Viral, Antibodies, Neutralizing, Mice, Inbred C57BL, Viral Envelope Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HIPRA, Agència de Gestió d'Ajuts Universitaris i de Recerca, Departament de Recerca i Universitats.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The envelope glycoprotein (Env) of retroviruses, such as the Feline leukemia virus (FeLV), is the main target of neutralizing humoral response, and therefore, a promising vaccine candidate, despite its reported poor immunogenicity. The incorporation of mutations that stabilize analogous proteins from other viruses in their prefusion conformation (e.g., HIV Env, SARS-CoV-2 S, or RSV F glycoproteins) has improved their capability to induce neutralizing protective immune responses. Therefore, we have stabilized the FeLV Env protein following a strategy based on the incorporation of a disulfide bond and an Ile/Pro mutation (SOSIP) previously used to generate soluble HIV Env trimers. We have characterized this SOSIP-FeLV Env in its soluble form and as a transmembrane protein present at high density on the surface of FeLV Gag-based VLPs. Furthermore, we have tested its immunogenicity in DNA-immunization assays in C57BL/6 mice. Low anti-FeLV Env responses were detected in SOSIP-FeLV soluble protein-immunized animals; however, unexpectedly no responses were detected in the animals immunized with SOSIP-FeLV Gag-based VLPs. In contrast, high humoral response against FeLV Gag was observed in the animals immunized with control Gag VLPs lacking SOSIP-FeLV Env, while this response was significantly impaired when the VLPs incorporated SOSIP-FeLV Env. Our data suggest that FeLV Env can be stabilized as a soluble protein and can be expressed in high-density VLPs. However, when formulated as a DNA vaccine, SOSIP-FeLV Env remains poorly immunogenic, a limitation that must be overcome to develop an effective FeLV vaccine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, ViralAntibodies, NeutralizingMice, Inbred C57BLViral Envelope ProteinsLeukemia Virus, FelineAnimalsMiceGene Products, gagFemaleVaccines, Virus-Like ParticleHumansCatsViral VaccinesImmunogenicity, Vaccine

Stichwörter der Autor:innen

EnvFeLVSOSIPvaccineveterinary sciencevirus-like particle (VLP)

Substanzen

Antibodies, ViralAntibodies, NeutralizingViral Envelope ProteinsGene Products, gagVaccines, Virus-Like ParticleViral Vaccines

Autor:innen und Institutionen

  • IrsiCaixa, 08916 Badalona, Spain.
  • Doctorate School, Microbiology Department, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
  • Centre for Health and Social Care Research (CESS), Faculty of Medicine, University of Vic-Central University of Catalonia (UVic-UCC), 08500 Vic, Spain.
  • HIPRA, 17170 Amer, Spain.
  • Infectious Diseases Department, Germans Trias I Pujol Hospital, 08916 Badalona, Spain.
  • Germans Trias I Pujol Research Institute (IGTP), 08916 Badalona, Spain.

ORCID-Profile: Raquel Ortiz, Anna Pons-Grífols, Benjamin Trinité, Ferran Tarrés-Freixas, Carla Rovirosa, Víctor Urrea, Antonio Barreiro, Carmen Aguilar-Gurrieri, Julià Blanco

Förderung

  • HIPRA
  • Agència de Gestió d'Ajuts Universitaris i de Recerca
  • Departament de Recerca i Universitats
  • Secretaria d’Universitats I Recerca of Generalitat de Catalunya together with the European Social Fund
  • CERCA and SGR Programs

Zitieren

APA

Ortiz, R., Barajas, A., Pons-Grífols, A., Trinité, B., Tarrés-Freixas, F., Rovirosa, C., Urrea, V., Barreiro, A., Gonzalez-Tendero, A., Rovira-Rigau, M., Cardona, M., Ferrer, L., Clotet, B., Carrillo, J., Aguilar-Gurrieri, C., & Blanco, J. (2024). Production and Immunogenicity of FeLV Gag-Based VLPs Exposing a Stabilized FeLV Envelope Glycoprotein. Viruses. https://doi.org/10.3390/v16060987

Vancouver

Ortiz R, Barajas A, Pons-Grífols A, Trinité B, Tarrés-Freixas F, Rovirosa C, et al. Production and Immunogenicity of FeLV Gag-Based VLPs Exposing a Stabilized FeLV Envelope Glycoprotein. Viruses. 2024. doi:10.3390/v16060987

BibTeX
@article{Ortiz2024,
  author = {Ortiz, Raquel and Barajas, Ana and Pons-Grífols, Anna and Trinité, Benjamin and Tarrés-Freixas, Ferran and Rovirosa, Carla and Urrea, Víctor and Barreiro, Antonio and Gonzalez-Tendero, Anna and Rovira-Rigau, Maria and Cardona, Maria and Ferrer, Laura and Clotet, Bonaventura and Carrillo, Jorge and Aguilar-Gurrieri, Carmen and Blanco, Julià},
  title = {Production and Immunogenicity of FeLV Gag-Based VLPs Exposing a Stabilized FeLV Envelope Glycoprotein},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16060987}
}
Kostenlos starten →